PARTICIPATION IN CALGB

UMCC在其科学和技术方面不断发展， 与CALGB的临床关系 UMCC教师参与 行政、科学、委员会和规划活动 在CALGB中。 UMCC教师设计，指挥和椅子 许多小组研究并输入大量患者（pts.） CALGB协议。 UMCC教师椅子两个主要 小组内的委员会，并负责调查 大量的研究。 资金继续和扩大 这些活动将使更多的国家和组织能够积极参与， UMCC在全组研究中。 例如，UMCC内部第一阶段 （每年2至4项）研究经常进入全集团范围的第II阶段 问题研究 UMCC还进行了试点研究， 集团范围研究的概念基础。 UMCC是唯一的 最大的盈利机构。 患有急性白血病 研究这种疾病的基础科学实验室是一个有价值的 资源到集团。 这些专业实验室包括 细胞遗传学和药理学，可作为 为今后的拉丁美洲和加勒比地区大不列颠及北爱尔兰联合王国提供合作努力和创新基础 交互式实验室/临床研究。 UMCC及其 合作机构（VA医疗中心-巴尔的摩; 特拉华州CCOP医疗中心）和大巴尔的摩 医疗中心）建议将应计费用进一步增加到250美元以上 每年纳入CALGB研究的方案条目。 这是一个 最大的一个。 参与CALGB研究将 使UMCC及其合作医生能够更好地治疗 pts的选项。 与该小组正在研究的疾病有关。 UMCC 目前进入pts。 急性白血病小细胞肺癌 癌症、乳腺癌和淋巴瘤。 辅助研究包括 评价细胞药理学和阿糖胞苷敏感性 作为白血病细胞的细胞遗传学， 甲氨蝶呤同步拆分技术。 许多当前 积极的CALGB集团范围的研究部分来自试点 来自UMCC的数据，包括在急性白血病、乳腺癌、 癌症，小细胞肺癌和UMCC实验室将 为这些激素研究提供药理学支持。 资助 基础科学实验室，如研究小细胞肺的实验室， 癌症生物学和生长调节作为团体资源， 交互式实验室临床试验。 UMCC试点研究， 乳腺癌激素治疗开辟了一个新领域 乳腺癌的治疗效果。 UMCC也 参与选定的CALGB II期研究，以及 罕见肿瘤进入组间研究， CALGB 这笔赠款将允许UMCC继续进入pts。 研究，并继续提供强有力的科学 参与团队科学和团队管理活动。 这笔赠款还将允许继续优秀的飞行员 协议，并将允许UMCC监控和收集数据， 将对UMCC和CALGB产生互惠互利。

The UMCC has had ever continuing growth in its scientific and clinical relationships with CALGB. UMCC faculty participate in administrative, scientific, committee and planning activities within the CALGB. The UMCC faculty design, conduct and chair many groups studies and enter large numbers of patients (pts.) onto CALGB protocols. UMCC faculty chair two major committees within the group and are the responsible investigators for a large number of studies. Funding to continue and expand these activities will allow for further strong participation of UMCC in groupwide studies. For example, UMCC inhouse phase I (2 to 4 per year) studies frequently evolve into groupwide phase II studies. UMCC also conducts pilot studies which have formed the conceptual bases for groupwide studies. UMCC is the single largest accruing institution for pts. with acute leukemia and the basic science laboratories studying this disease is a valuable resource to the group. These specialized laboratories include cytogenetics and pharmacology which serve as a resource for collaborative efforts and innovative bases for future CALGB interactive laboratory/clinical studies. UMCC and its collaborating institutions (VA Medical Center - Baltimore; Medical Center of Delaware CCOP), and Greater Baltimore Medical Center) propose to further increment accrual beyond 250 protocol entries per year onto CALGB studies. This accrual is one of the largest in the group. Participation in CALGB studies will allow UMCC and its collaborating physicians greater treatment options for pts. with diseases under study by the group. UMCC currently enters pts. onto trials in acute leukemia, small cell lung cancer, breast cancer, and lymphoma. Ancillary studies are evaluating cellular pharmacology and sensitivity of Ara-C as well as the cytogenetics of leukemia cells utilizing standard and methotrexate synchronized resolution techniques. Many currently active CALGB groupwide studies are derived in part from pilot data from the UMCC including studies in acute leukemia, breast cancer, and small cell lung cancer and UMCC laboratories will provide pharmacology support for these hormone studies. Funded basic science laboratories such as those studying small cell lung cancer biology and growth modulation act as group resources for interactive laboratory clinical trials. UMCC pilot studies in hormonal treatment of breast cancer have opened up a new area of treatment for the group in breast cancer. UMCC also participates in selected CALGB phase II studies as well as uncommon tumors entered onto intergroup studies through CALGB. This grant will allow UMCC to continue to enter pts. onto CALGB studies and continue to provide a strong scientific input into the group science and group administrative activities. This grant will also allow for the continuation of meritorious pilot protocols and will allow UMCC to monitor and collect data which will produce mutual benefit to the UMCC and the CALGB.